The role of ADC values within the normal-appearing brain in the prognosis of multiple sclerosis activity during interferon-β therapy in the 3-year follow-up: a preliminary report
Open Access
- 30 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 10 (1), 1-13
- https://doi.org/10.1038/s41598-020-69383-3
Abstract
Predictors of multiple sclerosis (MS) activity during disease-modifying treatment are being extensively investigated. The aim of this study was to assess the prognosis of NEDA (no evidence of disease activity) status during IFN-β (interferon-β) treatment, using apparent diffusion coefficient (ADC) measurements obtained at initial MRI (magnetic resonance imaging). In 87 MS patients treated with IFN-β, ADC values were calculated for 13 regions of normal-appearing white and grey matter (NAWM, NAGM) based on MRI performed with a 1.5 T magnet before (MS0, n = 45) or after one year of therapy (MS1, n = 42). Associations were evaluated between ADC, conventional MRI findings, demographic and clinical factors and NEDA status within the following 3 years using logistic, Cox and multinomial logistic regression models. NEDA rates in the MS0 group were 64.4%, 46.5% and 33.3% after the 1st, 2nd and 3rd year of treatment, respectively and in MS1 patients 71.4% and 48.7% for the periods 1st–2nd and 1st–3rd years of treatment, respectively. ADC values in the NAWM regions contributed to loss of NEDA and its clinical and radiological components, with a 1–3% increase in the risk of NEDA loss (p = 0.0001–0.0489) in both groups. ADC measurements may have an additional prognostic value with regard to NEDA status.This publication has 42 references indexed in Scilit:
- Immunomodulatory therapies delay disease progression in multiple sclerosisMultiple Sclerosis Journal, 2016
- A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathologyBrain, 2012
- Focal multiple sclerosis lesions abound in ‘normal appearing white matter’Multiple Sclerosis Journal, 2011
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Wallerian Degeneration: A Major Component of Early Axonal Pathology in Multiple SclerosisBrain Pathology, 2010
- One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosisEuropean Journal of Neurology, 2009
- Measures in the first year of therapy predict the response to interferon β in MSMultiple Sclerosis Journal, 2009
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyThe Lancet Neurology, 2009
- MRI activity and neutralising antibody as predictors of response to interferon treatment in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2007
- An introduction to ROC analysisPattern Recognition Letters, 2005